• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Friday 12/14/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Lodonal

  • 9:19 AM

    ORLANDO, Fla., Aug. 07, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE–Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and inflammatory conditions, cancer, HIV/AIDS and animal diseases on a global basis, announced today that Dr. Roscoe Moore Jr., DVM, MPH, Ph.D., DSc has joined the Company as Chairman of the Board and will also maintain a position on the Company’s

    Read more
  • 12:35 PM

    ORLANDO, Fla., July 19, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE– Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that their lead therapy, Lodonal (LDN), was featured in an article published in Plus Magazine:  https://www.hivplusmag.com/i-am-warrior/2018/7/12/will-needs-long-term-survivors-be-heard. Plus Magazine (formally HIVPlus Magazine) was founded in 1998 and is a leading direct to consumer publication providing cutting

    Read more
  • 11:56 AM

    ORLANDO, Fla., June 05, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune,” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS is pleased to announce a modification of the Company’s 2014 exclusive licensing agreement with Cytocom, Inc., a late stage biotechnology company that specializes in T-Cell activation immunotherapies. In addition to the rights granted

    Read more
  • 8:16 AM

    ORLANDO, Fla., April 26, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE– Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, is pleased to announce that the Kenya Pharmacy and Poison Board filed IMUN’s New Drug Application (NDA) for Lodonal™, its lead drug candidate, thereby accepting the NDA for a full review. Kenya is experiencing an HIV

    Read more
  • 9:22 AM

    ORLANDO, Fla., March 26, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE– Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 “Lodonal™” and IRT-101″MENK”) for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDs, today announces that it has received minutes from the Type C meeting held on January 16, 2018, between Immune Therapeutics on behalf of Cytocom, the license holder, and the US Food

    Read more
  • 8:44 AM

    ORLANDO, Fla., Feb. 20, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE– Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 “Lodonal” and IRT-101 “MENK”) for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDs,  today announced the company has shipped its initial order of Lodonal to AHAR Pharma in Nigeria.  In addition, IMUN has received both trademark and patent approval from the Federal

    Read more
Public Wire Banner